(Alliance News) - Biotech Growth Trust PLC, International Biotechnology Trust PLC, ad RTW Biotech Opportunities Ltd have all noted the agreement announced by Biogen Inc on Tuesday to acquire Apellis Pharmaceuticals, Inc. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it is "cautiously optimistic" looking ahead as it reported a sharply higher net asset value per share. Read More
(Alliance News) - London stocks were called to open lower on Monday, as the Iran war continues, while in UK company news, Burford Capital called a US appeals court decision on Argentina's nationalisation of oil company YPF in 2012 "very disappointing". Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Corxel Pharmaceuticals Ltd, RTW's largest private investment, has completed Series D-1 financing worth USD287 million. Says Corxel is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic conditions, and its lead candidate, CX11, is an oral GLP-1 receptor agonist for obese and overweight patients currently in a phase 2 US trial. Expects the financing proceeds to support the advancement of this trial, as well as a planned global phase 2 trial in type 2 diabetes mellitus and initial preparations for phase 3 studies and other cardiometabolic programmes. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday noted Boston Scientific Corp's USD14.5 billion acquisition of Penumbra Inc, a portfolio company that represented 1.0% of its net asset value at the end of 2025. Read More
(Alliance News) - Next confirms the redemption of B shares as part of its GBP421 million capital return, Johnson Service reports resilient 2025 trading with rising earnings, and Irish Residential Properties REIT announces a CFO transition. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said its portfolio company Aktis Oncology Inc has completed a USD318 million IPO on New York's Nasdaq, the first biotech listing of 2026. Read More
(Alliance News) - British Land CEO Simon Carter will step down after five years in the role, as Plus500 reports revenue and Ebitda ahead of expectations and Oxford Nanopore posts stronger-than-guided full-year sales growth, while Heathrow celebrates a record 84 million passengers in 2025. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said it participated in the series A funding round of clinical stage biotechnology company Yarrow Bioscience Inc ahead of its Nasdaq listing. Read More
(Alliance News) - Stock prices in London were mixed on Thursday, as the FTSE 100 missed out on a European rally amid weakness in SSE and National Grid after Ofgem approved a GBP28 billion investment. Read More
(Alliance News) - Rio Tinto says earnings could rise by up to 50% by 2030, SSE and National Grid welcome Ofgem's approval of GBP28 billion of energy investment and SSP swings to a loss. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted one of its private portfolio companies Evommune Inc raised USD150 million in its initial public offering. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday confirmed it has entered into a royalty funding agreement with clinical stage biopharmaceutical company Savara Inc for a rare lung disease treatment. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted that Swiss pharmaceutical major Novartis AG has definitively agreed to buy portfolio company Avidity Biosciences Inc. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in life sciences sector - Adds USD15 million to share buyback programme, aiming to close the discount of its share price to net asset value. RTW Biotech has USD5.8 million to complete from its current USD30 million buyback and will top that up by USD15 million, which is equivalent to about 9.2 million shares. Funds for the buyback come from several recent realisations of portfolio holdings. The company's most recently report net asset value, as of June 30, was USD1.70. Read More
(Alliance News) - RTW Biotech Opportunities Ltd said on Wednesday that it invested USD7.4 million in Kailera Therapeutics Inc for the company's USD600 million Series B financing round. Read More
(Alliance News) - Akero Therapeutics Inc on Friday said it will benefit from "industry-leading development capabilities and commercial infrastructure" through its acquisition by Novo Nordisk AS. Read More